Normative Database of Healthy Subject Vascular Density Using Spectralis Heidelberg® Optical Coherence Tomography Angiography
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Sep 19, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating a reference database for a specific eye imaging technology called Optical Coherence Tomography Angiography (OCT-A) using the Spectralis Heidelberg device. This technology helps doctors examine the blood vessels in the retina without needing to inject dye, which makes it safer and easier for patients. The goal is to gather information from healthy volunteers so that doctors can better understand how the blood vessels should look in healthy eyes compared to those with certain eye conditions.
To participate in this trial, you must be an adult (age 18 or older) in good health, with specific eye pressure and vision requirements. Unfortunately, people with certain eye diseases, diabetes, or high blood pressure, among other conditions, cannot join. If you decide to participate, you will undergo a non-invasive eye examination using the OCT-A technology, and your data will contribute to a valuable resource for future eye health studies. This study is currently recruiting participants, and your involvement could help improve eye care for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Voluntary adult subjects or legal representative consenting for minor or subjects under protection
- • Intra ocular pression ≤ 21mmHg
- • Spherical refraction comprised between - 6 D and +6 D and/or axial length between 21 and 26mm
- • Patient affiliated to social security system
- Exclusion Criteria:
- • Ocular diseases: glaucoma, retinal diseases as diabetic retinopathy, age-related macular degeneration, amblyopia, optic neuropathy
- • Diabetes mellitus
- • Uncontrolled hypertension blood pressure (\> 140/90)
- • Recent ocular surgery (\< 6 months)
- • Any ophthalmological conditions interfering with a good ocular examination or OCT quality (cataract, corneal opacity ...)
- • OCT-A sufficient quality ≥ 25 (0 = bad quality /40 = excellent quality
- • Not consenting patient
- • Pathological situation or handicap avoiding good installation
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported